[The future of peptic ulcer disease without Helicobacter].
Lehmann
F S
FS
Abteilung für Gastroenterologie, Departement für Innere Medizin, Universitätsspital Basel.
Gyr
N
N
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D000068579:Celecoxib; D002648:Child; D004311:Double-Blind Method; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000453:epidemiology*; D016480:Helicobacter pylori; D006801:Humans; D015994:Incidence; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D015201:Meta-Analysis as Topic; D010003:Osteoarthritis / Q000188:drug therapy; D010437:Peptic Ulcer / Q000139:chemically induced / Q000453:epidemiology* / Q000209:etiology; D015995:Prevalence; D011720:Pyrazoles; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib; D001241:Aspirin
Stirbt die Ulkuskrankheit ohne Helicobacter aus?